

Laura Fugazzola

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/177925/publications.pdf>

Version: 2024-02-01

81
papers

4,470
citations

145106

33
h-index

120465

65
g-index

85
all docs

85
docs citations

85
times ranked

4670
citing authors

#	ARTICLE	IF	CITATIONS
1	Medullary thyroid cancer - An update. Best Practice and Research in Clinical Endocrinology and Metabolism, 2023, 37, 101655.	2.2	8
2	Thyroid pathology and female fertility: Myth or reality?. Annales D'Endocrinologie, 2022, 83, 168-171.	0.6	5
3	FAM83B is involved in thyroid cancer cell differentiation and migration. Scientific Reports, 2022, 12, .	1.6	0
4	How can we prevent disease relapse in Gravesâ€™ orbitopathy after immunosuppressive treatment?. Expert Review of Endocrinology and Metabolism, 2022, 17, 269-274.	1.2	1
5	Real-World Performance of the American Thyroid Association Risk Estimates in Predicting 1-Year Differentiated Thyroid Cancer Outcomes: A Prospective Multicenter Study of 2000 Patients. Thyroid, 2021, 31, 264-271.	2.4	40
6	Fine needle aspiration wash out for thyroglobulin determination in the differential diagnosis of lung lesions. Endocrine, 2021, 71, 253-255.	1.1	1
7	Basal and stimulated calcitonin for the diagnosis of medullary thyroid cancer: updated thresholds and safety assessment. Journal of Endocrinological Investigation, 2021, 44, 587-597.	1.8	24
8	Lenvatinib as first-line treatment for advanced thyroid cancer: long progression-free survival. Endocrine, 2021, 72, 462-469.	1.1	15
9	ASO Author Reflections: Total Thyroidectomy Versus Lobectomy for Differentiated Thyroid Cancer. Annals of Surgical Oncology, 2021, 28, 4345-4346.	0.7	0
10	Total Thyroidectomy Versus Lobectomy for Thyroid Cancer: Single-Center Data and Literature Review. Annals of Surgical Oncology, 2021, 28, 4334-4344.	0.7	22
11	Personalized treatment for differentiated thyroid cancer: current data and new perspectives. Minerva Endocrinology, 2021, 46, 62-89.	0.6	6
12	Combined Mutational and Clonality Analyses Support the Existence of Intra-Tumor Heterogeneity in Papillary Thyroid Cancer. Journal of Clinical Medicine, 2021, 10, 2645.	1.0	3
13	<i>BRAF</i> V600E Status Sharply Differentiates Lymph Node Metastasis-associated Mortality Risk in Papillary Thyroid Cancer. Journal of Clinical Endocrinology and Metabolism, 2021, 106, 3228-3238.	1.8	36
14	Post-Surgical Ablative or Adjuvant Radioiodine Therapy Has No Impact on Outcome in 1-4 cm Differentiated Thyroid Cancers without Extrathyroidal Extension. Journal of Clinical Medicine, 2021, 10, 4452.	1.0	0
15	Basal and Calcium-Stimulated Procalcitonin for the Diagnosis of Medullary Thyroid Cancers: Lights and Shadows. Frontiers in Endocrinology, 2021, 12, 754565.	1.5	9
16	Body Composition and Leptin/Ghrelin Levels during Lenvatinib for Thyroid Cancer. European Thyroid Journal, 2020, 9, 1-10.	1.2	10
17	Molecular markers for the classification of cytologically indeterminate thyroid nodules. Journal of Endocrinological Investigation, 2020, 43, 703-716.	1.8	34
18	BRAF V600E status may facilitate decision-making on active surveillance of low-risk papillary thyroid microcarcinoma. European Journal of Cancer, 2020, 124, 161-169.	1.3	41

#	ARTICLE	IF	CITATIONS
19	The molecular and gene/miRNA expression profiles of radioiodine resistant papillary thyroid cancer. <i>Journal of Experimental and Clinical Cancer Research</i> , 2020, 39, 245.	3.5	27
20	Clinical and Genetic Features of a Large Monocentric Series of Familial Non-Medullary Thyroid Cancers. <i>Frontiers in Endocrinology</i> , 2020, 11, 589340.	1.5	8
21	2021 European Thyroid Association Guideline on Thyroid Disorders prior to and during Assisted Reproduction. <i>European Thyroid Journal</i> , 2020, 9, 281-295.	1.2	91
22	Intratumoral Genetic Heterogeneity in Papillary Thyroid Cancer: Occurrence and Clinical Significance. <i>Cancers</i> , 2020, 12, 383.	1.7	31
23	2019 European Thyroid Association Guidelines for the Treatment and Follow-Up of Advanced Radioiodine-Refractory Thyroid Cancer. <i>European Thyroid Journal</i> , 2019, 8, 227-245.	1.2	179
24	Primary Adrenal Insufficiency During Lenvatinib or Vandetanib and Improvement of Fatigue After Cortisone Acetate Therapy. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 779-784.	1.8	35
25	Genetic variants of PARP4 gene and PARP4P2 pseudogene in patients with multiple primary tumors including thyroid cancer. <i>Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis</i> , 2019, 816-818, 111672.	0.4	3
26	Baseline and stimulated calcitonin: Thresholds for the diagnosis of medullary thyroid cancer. <i>Annales D'Endocrinologie</i> , 2019, 80, 191-192.	0.6	4
27	<i>DUOX2</i> Mutations Frequently Cause Congenital Hypothyroidism that Evades Detection on Newborn Screening in the United Kingdom. <i>Thyroid</i> , 2019, 29, 790-801.	2.4	26
28	Absence of the <i>MAP2K5</i> germline variants c.G961A and c.T1100C in a wide series of familial nonmedullary thyroid carcinoma Italian families. <i>International Journal of Cancer</i> , 2019, 145, 600-600.	2.3	13
29	Natural history, treatment, and long-term follow up of patients with multiple endocrine neoplasia type 2B: an international, multicentre, retrospective study. <i>Lancet Diabetes and Endocrinology</i> , 2019, 7, 213-220.	5.5	86
30	Impact of Mutation Density and Heterogeneity on Papillary Thyroid Cancer Clinical Features and Remission Probability. <i>Thyroid</i> , 2019, 29, 237-251.	2.4	31
31	BRAF V600E Mutation-Assisted Risk Stratification of Solitary Intrathyroidal Papillary Thyroid Cancer for Precision Treatment. <i>Journal of the National Cancer Institute</i> , 2018, 110, 362-370.	3.0	60
32	Circulating miR-375 as a novel prognostic marker for metastatic medullary thyroid cancer patients. <i>Endocrine-Related Cancer</i> , 2018, 25, 217-231.	1.6	50
33	MassARRAY-based simultaneous detection of hotspot somatic mutations and recurrent fusion genes in papillary thyroid carcinoma: the PTC-MA assay. <i>Endocrine</i> , 2018, 61, 36-41.	1.1	13
34	Letter regarding the article: "Multiple HABP2 variants in familial papillary thyroid carcinoma: Contribution of a group of thyroid-checked controls" by Kern et al.. <i>European Journal of Medical Genetics</i> , 2018, 61, 104-105.	0.7	7
35	Genetics and management of congenital hypothyroidism. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2018, 32, 387-396.	2.2	52
36	Italian consensus on diagnosis and treatment of differentiated thyroid cancer: joint statements of six Italian societies. <i>Journal of Endocrinological Investigation</i> , 2018, 41, 849-876.	1.8	165

#	ARTICLE	IF	CITATIONS
37	Genetic Factors in Thyroid Disease. , 2018, , 496-505.		1
38	Segregation and expression analyses of hyaluronan-binding protein 2 (HABP2): insights from a large series of familial non-medullary thyroid cancers and literature review. <i>Clinical Endocrinology</i> , 2017, 86, 837-844.	1.2	13
39	Digenic DUOX1 and DUOX2 Mutations in Cases With Congenital Hypothyroidism. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017, 102, 3085-3090.	1.8	53
40	Disorders of H ₂ O ₂ generation. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2017, 31, 225-240.	2.2	52
41	The Prognostic Value of Tumor Multifocality in Clinical Outcomes of Papillary Thyroid Cancer. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017, 102, 3241-3250.	1.8	80
42	Multicellular spheroids from normal and neoplastic thyroid tissues as a suitable model to test the effects of multikinase inhibitors. <i>Oncotarget</i> , 2017, 8, 9752-9766.	0.8	14
43	Oxidative stress and the subcellular localization of the telomerase reverse transcriptase (TERT) in papillary thyroid cancer. <i>Molecular and Cellular Endocrinology</i> , 2016, 431, 54-61.	1.6	23
44	Novel insights into the link between fetal cell microchimerism and maternal cancers. <i>Journal of Cancer Research and Clinical Oncology</i> , 2016, 142, 1697-1704.	1.2	16
45	Basal and stimulated calcitonin levels in patients with type 2 diabetes did not change during 1 year of Liraglutide treatment. <i>Metabolism: Clinical and Experimental</i> , 2016, 65, 1-6.	1.5	17
46	Fetal cell microchimerism in papillary thyroid cancer: A role in the outcome of the disease. <i>International Journal of Cancer</i> , 2015, 137, 2989-2993.	2.3	12
47	Fetal cell microchimerism: a protective role in autoimmune thyroid diseases. <i>European Journal of Endocrinology</i> , 2015, 173, 111-118.	1.9	16
48	Impact of estrogen and progesterone receptor expression on the clinical and molecular features of papillary thyroid cancer. <i>European Journal of Endocrinology</i> , 2015, 173, 29-36.	1.9	60
49	The modifier role of RET-G691S polymorphism in hereditary medullary thyroid carcinoma: functional characterization and expression/penetrance studies. <i>Orphanet Journal of Rare Diseases</i> , 2015, 10, 25.	1.2	24
50	Reference Range of Serum Calcitonin in Pediatric Population. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, 1780-1784.	1.8	40
51	Telomerase in differentiated thyroid cancer: Promoter mutations, expression and localization. <i>Molecular and Cellular Endocrinology</i> , 2015, 399, 288-295.	1.6	100
52	SP600125 has a remarkable anticancer potential against undifferentiated thyroid cancer through selective action on ROCK and p53 pathways. <i>Oncotarget</i> , 2015, 6, 36383-36399.	0.8	32
53	Positive effect of fetal cell microchimerism on tumor presentation and outcome in papillary thyroid cancer. <i>Chimerism</i> , 2014, 5, 106-108.	0.7	4
54	The Clinical and Molecular Characterization of Patients With Dysmorphogenic Congenital Hypothyroidism Reveals Specific Diagnostic Clues for DUOX2 Defects. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, E544-E553.	1.8	69

#	ARTICLE	IF	CITATIONS
55	Refining Calcium Test for the Diagnosis of Medullary Thyroid Cancer: Cutoffs, Procedures, and Safety. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, 1656-1664.	1.8	98
56	The optimal range of RET mutations to be tested: European comments to the guidelines of the American Thyroid Association. <i>Thyroid Research</i> , 2013, 6, S8.	0.7	11
57	Association Between BRAF V600E Mutation and Mortality in Patients With Papillary Thyroid Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2013, 309, 1493.	3.8	775
58	Stimulated Calcitonin Cut-Offs by Different Tests. <i>European Thyroid Journal</i> , 2013, 2, 49-56.	1.2	22
59	Comparison of Calcium and Pentagastrin Tests for the Diagnosis and Follow-Up of Medullary Thyroid Cancer. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012, 97, 905-913.	1.8	95
60	The Primary Occurrence of <i>BRAF</i> ^{V600E} Is a Rare Clonal Event in Papillary Thyroid Carcinoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012, 97, 517-524.	1.8	134
61	A High Percentage of BRAFV600E Alleles in Papillary Thyroid Carcinoma Predicts a Poorer Outcome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012, 97, 2333-2340.	1.8	112
62	Microchimerism and Endocrine Disorders. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012, 97, 1452-1461.	1.8	25
63	Papillary Thyroid Carcinoma and Inflammation. <i>Frontiers in Endocrinology</i> , 2011, 2, 88.	1.5	15
64	Fetal cell microchimerism in papillary thyroid cancer: studies in peripheral blood and tissues. <i>International Journal of Cancer</i> , 2010, 126, 2874-2878.	2.3	35
65	The tight relationship between papillary thyroid cancer, autoimmunity and inflammation: clinical and molecular studies. <i>Clinical Endocrinology</i> , 2010, 72, 702-708.	1.2	147
66	Clinical and molecular features of differentiated thyroid cancer diagnosed during pregnancy. <i>European Journal of Endocrinology</i> , 2010, 162, 145-151.	1.9	106
67	Four novel RET germline variants in exons 8 and 11 display an oncogenic potential in vitro. <i>European Journal of Endocrinology</i> , 2010, 162, 771-777.	1.9	28
68	Multiple endocrine neoplasia type 2 syndromes (MEN 2): results from the ItaMEN network analysis on the prevalence of different genotypes and phenotypes. <i>European Journal of Endocrinology</i> , 2010, 163, 301-308.	1.9	111
69	Outcome predictors and impact of central node dissection and radiometabolic treatments in papillary thyroid cancers. <i>Endocrine-Related Cancer</i> , 2009, 16, 201-210.	1.6	50
70	Fetal Cell Microchimerism in Papillary Thyroid Cancer: A Possible Role in Tumor Damage and Tissue Repair. <i>Cancer Research</i> , 2008, 68, 8482-8488.	0.4	70
71	Biallelic Inactivation of the Dual Oxidase Maturation Factor 2 (DUOXA2) Gene as a Novel Cause of Congenital Hypothyroidism. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2008, 93, 605-610.	1.8	157
72	Histopathological and molecular studies in patients with goiter and hypercalcitoninemia: reactive or neoplastic C-cell hyperplasia?. <i>Endocrine-Related Cancer</i> , 2007, 14, 393-403.	1.6	34

#	ARTICLE	IF	CITATIONS
73	Correlation between B-RAFV600E mutation and clinico-pathologic parameters in papillary thyroid carcinoma: data from a multicentric Italian study and review of the literature. <i>Endocrine-Related Cancer</i> , 2006, 13, 455-464.	1.6	207
74	An in-frame complex germline mutation in the juxtamembrane intracellular domain causing RET activation in familial medullary thyroid carcinoma. <i>Endocrine-Related Cancer</i> , 2006, 13, 945-953.	1.6	12
75	Persistent mild hypothyroidism associated with novel sequence variants of the DUOX2 gene in two siblings. <i>Human Mutation</i> , 2005, 26, 395-395.	1.1	105
76	BRAF mutations in an Italian cohort of thyroid cancers. <i>Clinical Endocrinology</i> , 2004, 61, 239-243.	1.2	167
77	Frequent association between MEN 2A and cutaneous lichen amyloidosis. <i>Clinical Endocrinology</i> , 2003, 59, 156-161.	1.2	119
78	Multigenerational familial medullary thyroid cancer (FMTC): evidence for FMTC phenocopies and association with papillary thyroid cancer. <i>Clinical Endocrinology</i> , 2002, 56, 53-63.	1.2	42
79	The role of pendrin in iodide regulation. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2001, 109, 18-22.	0.6	22
80	Unilateral Surgery for Medullary Thyroid Carcinoma: Seeking for Clinical Practice Guidelines. <i>Frontiers in Endocrinology</i> , 0, 13, .	1.5	5
81	Daily Management of Patients on Multikinase Inhibitors™ Treatment. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	3